ClinicalTrials.gg
CompletedNCT03478787Updated Jul 13, 2021Results posted

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of risankizumab and secukinumab in Psoriasis, sponsored by AbbVie. Completed at 61 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-13.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
18 Years and older
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
8th of 30
327 · median 162
Started
2018
with 2 others
Phase 3
17 of 30
none open now
Registered
14th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 8th largest by enrollment, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 14th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months before the Baseline Visit
  • Subject has stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis
  • Subject must be a candidate for systemic therapy as assessed by the investigator;
  • Subject must be an acceptable candidate to receive secukinumab according to the local label for this compound.

Exclusion criteria

Exclusion Criteria:

  • History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis; or active skin disease other than psoriasis that could interfere with the assessment of psoriasis;
  • Chronic infections including , viral hepatitis (, ), and/ or active tuberculosis. Subjects with a positive QuantiFERON®-TB/purified protein derivative (PPD) test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines.
  • Active systemic infection during the last 2 weeks prior to Baseline Visit (exception: common cold)
  • History of any documented active or suspected or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix
  • Previous exposure to risankizumab
  • Previous exposure to secukinumab
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    Risankizumab

    Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).

    Drug: risankizumab

  • Active comparator
    Secukinumab

    Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.

    Drug: secukinumab

Interventions

  • Subcutaneous (SC) injection

    Also known as: ABBV-066, BI 655066, SKYRIZI

  • Subcutaneous (SC) injection

    Also known as: Cosentyx

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16

    The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Non-responder imputation (NRI) was used for missing data.

    Time frame: Week 16

  2. Percentage of Participants With a PASI 90 at Week 52

    The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants With a 100% Reduction From Baseline Psoriasis Area and Severity Index (PASI 100) at Week 52

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: Week 52

  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 52

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all 3; Almost clear (1) = mean \> 0, \< 1.5; Mild (2) = mean ≥ 1.5, \< 2.5; Moderate (3) = mean ≥ 2.5, \< 3.5; and Severe (4) = mean ≥ 3.5.

    Time frame: Week 52

  3. Percentage of Participants With a 75% Reduction From Baseline Psoriasis Area and Severity Index (PASI 75) at Week 52

    The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: Week 52

07

Results

Posted Jul 13, 2021

Participant flow

A total of 327 participants were randomized from 53 sites across 9 countries including Canada, France, Germany, Italy, The Netherlands, Poland, Spain, the United Kingdom, and the United States.

Participant flow — Overall Study
MilestoneSecukinumabRisankizumab
Started163164
Completed134151
Not completed2913
Withdrew: Adverse event51
Withdrew: Protocol violation30
Withdrew: Lack of efficacy71
Withdrew: Lost to follow-up95
Withdrew: Withdrawal by subject26
Withdrew: Other, not specified30

Outcome measures

PrimaryPercentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16

The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Non-responder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16
percentage of participantsSecukinumabRisankizumab
Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 1665.673.8
Statistical analysis
  • Secukinumab vs Risankizumab · Adjusted percentage difference: 8.2 · 96.25% CI -2.2 to 18.6Across the strata, 96.25% confidence interval (CI) for adjusted difference was calculated according to the Cochran-Mantel-Haenszel test for the comparison of 2 treatment groups.
PrimaryPercentage of Participants With a PASI 90 at Week 52

The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI 90 at Week 52
percentage of participantsSecukinumabRisankizumab
Percentage of Participants With a PASI 90 at Week 5257.186.6
Statistical analysis
  • Secukinumab vs Risankizumab · Cochran-Mantel-Haenszel · p = < 0.001 (Across the strata, p-value was calculated from the from the Cochran-Mantel-Haenszel test adjusted for strata.) · Adjusted percentage difference: 29.8 · 95% CI 20.8 to 38.8Across the strata, 95% CI for adjusted difference was calculated according to the Cochran-Mantel-Haenszel test for the comparison of 2 treatment groups.
SecondaryPercentage of Participants With a 100% Reduction From Baseline Psoriasis Area and Severity Index (PASI 100) at Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a 100% Reduction From Baseline Psoriasis Area and Severity Index (PASI 100) at Week 52
percentage of participantsSecukinumabRisankizumab
Percentage of Participants With a 100% Reduction From Baseline Psoriasis Area and Severity Index (PASI 100) at Week 5239.965.9
Statistical analysis
  • Secukinumab vs Risankizumab · Cochran-Mantel-Haenszel · p = < 0.001 (Across the strata, p-value was calculated from the from the Cochran-Mantel-Haenszel test adjusted for strata.) · Adjusted percentage difference: 26.2 · 95% CI 15.9 to 36.5Across the strata, 95% CI for adjusted difference was calculated according to the Cochran-Mantel-Haenszel test for the comparison of 2 treatment groups.
SecondaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 52

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all 3; Almost clear (1) = mean \> 0, \< 1.5; Mild (2) = mean ≥ 1.5, \< 2.5; Moderate (3) = mean ≥ 2.5, \< 3.5; and Severe (4) = mean ≥ 3.5.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 52
percentage of participantsSecukinumabRisankizumab
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 5258.387.8
Statistical analysis
  • Secukinumab vs Risankizumab · Cochran-Mantel-Haenszel · p = < 0.001 (Across the strata, p-value was calculated from the from the Cochran-Mantel-Haenszel test adjusted for strata.) · Adjusted percentage difference: 29.8 · 95% CI 20.9 to 38.8Across the strata, 95% CI for adjusted difference was calculated according to the Cochran-Mantel-Haenszel test for the comparison of 2 treatment groups.
SecondaryPercentage of Participants With a 75% Reduction From Baseline Psoriasis Area and Severity Index (PASI 75) at Week 52

The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a 75% Reduction From Baseline Psoriasis Area and Severity Index (PASI 75) at Week 52
percentage of participantsSecukinumabRisankizumab
Percentage of Participants With a 75% Reduction From Baseline Psoriasis Area and Severity Index (PASI 75) at Week 5269.989.6
Statistical analysis
  • Secukinumab vs Risankizumab · Cochran-Mantel-Haenszel · p = < 0.001 (Across the strata, p-value was calculated from the from the Cochran-Mantel-Haenszel test adjusted for strata.) · Adjusted percentage difference: 20.0 · 95% CI 11.7 to 28.3Across the strata, 95% CI for adjusted difference was calculated according to the Cochran-Mantel-Haenszel test for the comparison of 2 treatment groups.

Adverse events

Collected over Treatment-emergent adverse events are reported from first dose of study drug through 20 weeks after last dose of study drug (up to Week 68 for the Secukinumab arm, and up to Week 84 for the Risankizumab arm).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab0/163 (0%)6/163 (3.7%)71/163 (43.6%)
Risankizumab0/164 (0%)9/164 (5.5%)66/164 (40.2%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSecukinumabRisankizumab
URINARY TRACT INFECTIONInfections and infestations0/1632/164
COLITIS ULCERATIVEGastrointestinal disorders1/1630/164
DIVERTICULUM INTESTINAL HAEMORRHAGICGastrointestinal disorders1/1630/164
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/1630/164
CHOLELITHIASISHepatobiliary disorders1/1630/164
OVERDOSEInjury, poisoning and procedural complications1/1630/164
TOXIC ENCEPHALOPATHYNervous system disorders1/1630/164
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/1630/164
RASH PRURITICSkin and subcutaneous tissue disorders1/1630/164
ARTERIOSCLEROSISVascular disorders1/1630/164
Most frequent other events
Most frequent other events
EventSecukinumabRisankizumab
NASOPHARYNGITISInfections and infestations27/16335/164
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations14/16321/164
HEADACHENervous system disorders15/1639/164
BRONCHITISInfections and infestations11/1633/164
ARTHRALGIAMusculoskeletal and connective tissue disorders10/1639/164
DIARRHOEAGastrointestinal disorders9/1639/164
HYPERTENSIONVascular disorders5/1639/164

Baseline characteristics

Age, Customized
Age, Customized(Participants)SecukinumabRisankizumabTotal
< 40 years6050110
40 to < 65 years8199180
>/= 65 years221537
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabRisankizumabTotal
Female6252114
Male101112213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SecukinumabRisankizumabTotal
Hispanic or Latino343771
Not Hispanic or Latino129127256
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SecukinumabRisankizumabTotal
American Indian or Alaska Native011
Asian11617
Native Hawaiian or Other Pacific Islander202
Black or African American6612
White144151295
More than one race000
Unknown or Not Reported000
08

Study locations

61 sites
  • Advanced Research Associates - Glendale /ID# 204335
    Glendale, Arizona 85308, United States
  • Alliance Dermatology and MOHs /ID# 204336
    Phoenix, Arizona 85032, United States
  • Bakersfield Derma & Skin Cance /ID# 202115
    Bakersfield, California 93309, United States
  • Center for Dermatology Clin Res /ID# 202116
    Fremont, California 94538, United States
  • Dermatology Res. Assoc., CA /ID# 202170
    Los Angeles, California 90045, United States
  • UC Davis Health /ID# 202263
    Sacramento, California 95816, United States
  • Medderm Associates /ID# 202162
    San Diego, California 92103, United States
  • UConn Health Main /ID# 201745
    Farmington, Connecticut 06032, United States
  • Tory P Sullivan, MD PA /ID# 202177
    North Miami Beach, Florida 33162-4708, United States
  • Renstar Medical Research /ID# 202113
    Ocala, Florida 34470, United States
  • Progressive Medical Research /ID# 202183
    Port Orange, Florida 32127, United States
  • Integrated Clinical Research LLC /ID# 202152
    West Palm Beach, Florida 33406-6063, United States
  • Dermatology Specialists Resear /ID# 202145
    Louisville, Kentucky 40241, United States
  • Dermatology and Skin Cancer Specialists, LLC /ID# 203938
    Rockville, Maryland 20850, United States
  • ORA, Inc. /ID# 204342
    Andover, Massachusetts 01810, United States
  • Beth Israel Deaconess Medical Center /ID# 204340
    Boston, Massachusetts 02215-5400, United States
  • Minnesota Clinical Study Center /ID# 202369
    New Brighton, Minnesota 55112, United States
  • Central Dermatology, PC /ID# 202156
    Saint Louis, Missouri 63117, United States
  • Psoriasis Treatment Ctr of Central NJ /ID# 202107
    East Windsor, New Jersey 08520, United States
  • Synexus Research Cincinnati /ID# 202161
    Cincinnati, Ohio 45236, United States
  • Oregon Derm & Res. Ctr /ID# 201652
    Portland, Oregon 97210, United States
  • Oregon Medical Res Center PC /ID# 201651
    Portland, Oregon 97223, United States
  • Clinical Partners, LLC /ID# 201736
    Johnston, Rhode Island 02919, United States
  • Center for Clinical Studies - Houston (Binz) /ID# 202178
    Houston, Texas 77004-8097, United States
  • Progressive Clinical Research /ID# 202155
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies - Webster TX /ID# 202154
    Webster, Texas 77598, United States
  • University of Utah /ID# 204035
    Salt Lake City, Utah 84112-5500, United States
  • Froedtert Mem Lutheran Hosp /ID# 204896
    Milwaukee, Wisconsin 53226, United States
  • Beacon Dermatology Inc /ID# 203054
    Calgary, Alberta T3E 0B2, Canada
  • Enverus Medical Research /ID# 203043
    Surrey, British Columbia V3V 0C6, Canada
  • Dr. Irina Turchin PC Inc. /ID# 203052
    Fredericton, New Brunswick E3B 1G9, Canada
  • Eastern Canada Cutaneous Resea /ID# 203045
    Halifax, Nova Scotia B3H 1Z2, Canada
  • Dermatrials Research /ID# 203051
    Hamilton, Ontario L8N 1Y2, Canada
  • Dre Angelique Gagne-Henley M.D. inc. /ID# 203053
    Saint-Jerome, Quebec J7Z 7E2, Canada
  • Dermatologique du Quebec /ID# 203050
    Quebec, G1V 4X7, Canada
  • Charles Nicolle CHU Rouen /ID# 203590
    Rouen CEDEX, Seine-Maritime 76031, France
  • Centre Hospitalier Universitaire de Nice - Hopital l'Archet 2 /ID# 203591
    Nice, 06202, France
  • Hopital Saint-Louis /ID# 203586
    Paris, 75010, France
  • Polyclinique Courlancy /ID# 203588
    Reims, 51100, France
  • Hopital Larrey - CHU de Toulouse /ID# 203587
    Toulouse, 31059, France
  • TU Uniklinik Munchen /ID# 203919
    Munich, 80802, Germany
  • Policlinico A. Gemelli /ID# 203009
    Roma, Lazio 00168, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 204982
    Milan, Lombardia 20122, Italy
  • Radboud Universitair Medisch Centrum /ID# 202560
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Bravis Ziekenhuis /ID# 205232
    Bergen op Zoom, Noord-Brabant 4624 VT, Netherlands
  • Academisch Medical center Amsterdam /ID# 202556
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Dermed Centrum Medyczne Sp. z o.o /ID# 203171
    Lodz, Lodzkie 90-265, Poland
  • Klinika Dermatologii Pod Fortem /ID# 204180
    Krakow, Malopolskie 31-302, Poland
  • Przychodnia Specjalistyczna High-Med /ID# 203183
    Warsaw, Mazowieckie 01-817, Poland
  • Klinika Ambroziak Sp. z o.o. /ID# 203928
    Warsaw, Mazowieckie 02-758, Poland
  • KSW nr1 w Rzeszowie /ID# 203776
    Rzeszow, Podkarpackie 35-055, Poland
  • Osteo-Medic S.C. /ID# 203742
    Białystok, Podlaskie 15-351, Poland
  • Hospital de Manises /ID# 203757
    Manises, Valencia 46940, Spain
  • Hospital General Universitario Alicante /ID# 203764
    Alicante, 03010, Spain
  • Hospital Universitario Clinico San Cecilio /ID# 203760
    Granada, 18016, Spain
  • Hospital Universitario de la Princesa /ID# 203754
    Madrid, 28006, Spain
  • Hospital Universitario 12 de Octubre /ID# 203756
    Madrid, 28041, Spain
  • Hospital Universitario Arnau Vilanova /ID# 203763
    Valencia, 46015, Spain
  • Whipps Cross Univ Hospital /ID# 204723
    London, London, City Of E11 1NR, United Kingdom
  • Guy's and St Thomas' NHS Found /ID# 204721
    London, London, City Of SE1 9RT, United Kingdom
  • The University of Manchester /ID# 204720
    Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatol Ther (Heidelb). 2022 Feb;12(2):561-575. doi: 10.1007/s13555-021-00679-6. Epub 2022 Jan 20. PubMed 35050485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jul 2020, 26 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Mar 27, 2018
StartActual
May 8, 2018
Primary completionActual
Jul 8, 2020
CompletionActual
Jul 8, 2020
Results first posted
Jul 13, 2021
Last update
Jul 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03478787
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
May 8, 2018
Primary completion
Jul 8, 2020
Completion
Jul 8, 2020
Results posted
Jul 13, 2021
Last update
Jul 13, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion